StratifiCare
StratifiCare is a Singapore-based company founded in 2015, specializing in the development and manufacturing of in-vitro diagnostic (IVD) assay solutions for personalized medicine. They aim to optimize clinical outcomes by integrating protein diagnostics with artificial intelligence, enabling precision healthcare. Their product offerings include StratifiDen, a patented test to predict severe dengue by measuring specific biomarkers, and StratifiREY, which uses white blood cell biomarkers to predict a patient's response to Y90 radioembolization for liver cancer. StratifiCare emphasizes a mission to revolutionize healthcare through innovative diagnostics, with a vision to lead in protein diagnostic technologies and AI, collaborate with healthcare institutions, empower providers and patients, and positively impact society. The company has a team with significant expertise in virology, business development, and regulatory affairs, including a founder with 7 patents.
StratifiCare
StratifiCare is a Singapore-based company founded in 2015, specializing in the development and manufacturing of in-vitro diagnostic (IVD) assay solutions for personalized medicine. They aim to optimize clinical outcomes by integrating protein diagnostics with artificial intelligence, enabling precision healthcare. Their product offerings include StratifiDen, a patented test to predict severe dengue by measuring specific biomarkers, and StratifiREY, which uses white blood cell biomarkers to predict a patient's response to Y90 radioembolization for liver cancer. StratifiCare emphasizes a mission to revolutionize healthcare through innovative diagnostics, with a vision to lead in protein diagnostic technologies and AI, collaborate with healthcare institutions, empower providers and patients, and positively impact society. The company has a team with significant expertise in virology, business development, and regulatory affairs, including a founder with 7 patents.